GNPX 10-Q filed 2026-11-13 | Key takeaways
GNPX filed its 10-Q; the most relevant disclosure change is expanded Going concern disclosure: The company disclosed substantial doubt about its ability to continue as a going concern within one year after the financial statement date due to recurring losses from operations and need for additional financing to fund operating and capital requirements.
Key takeaways
Net loss widened to $4.2 million in Q3 2026 versus $3.8 million in Q3 2025, as R&D expenses increased 25% year-over-year to $2.7 million.
Cash position increased to $15.3 million at September 30, 2026, from $7.8 million at December 31, 2025, after raising $18.7 million in net proceeds from ATM stock sales in the nine-month period.
The company completed a 1-for-22 reverse stock split on July 16, 2026, following a 1-for-50 reverse split on October 21, 2025.
Genprex sold 993,436 shares for net proceeds of $18.73 million under the 2023 ATM Facility during the nine months ended September 30, 2026, with no sales under the 2025 ELOC Facility during the same period.
The company disclosed it has no revenue, has sustained substantial losses since inception, and raised substantial doubt about its ability to continue as a going concern within one year after the financial statement date.
The company added a new license agreement with UTHealth Houston in May 2025 for glioblastoma treatment rights and a new sponsored research agreement with MD Anderson in April 2026 for biomarker studies with a projected cost of approximately $2.8 million.
Subsequent to quarter end, the company sold 110,612 additional shares for approximately $0.27 million in net proceeds under the 2023 ATM Facility from October 1, 2026 through the filing date.
Key metrics
Disclosure changes
- Going concern disclosure
The company disclosed substantial doubt about its ability to continue as a going concern within one year after the financial statement date due to recurring losses from operations and need for additional financing to fund operating and capital requirements.
Indicates heightened liquidity risk and need for continued capital raises to fund operations. - Intellectual property portfolio
As of September 30, 2026, Genprex owned or had exclusive license agreements on 19 granted patents and 23 pending patent applications worldwide, up from 17 granted patents previously.
Reflects ongoing investment in IP protection for gene therapy technologies. - License agreements - new additions
Added new license agreement with UTHealth Houston (May 2025) for glioblastoma treatment rights and new license agreement with NYU (April 2025) for mesothelioma treatment rights.
Expands pipeline to include glioblastoma and mesothelioma as potential indications. - Sponsored research agreement - MD Anderson biomarker study
In April 2026, Genprex entered into a three-year sponsored research agreement with MD Anderson to study biomarkers that may predict patient response to REQORSA with a projected total cost of approximately $2.8 million.
Significant commitment to biomarker research for patient selection in clinical trials. - Reverse stock split
On July 16, 2026, Genprex completed a 1-for-22 reverse stock split of its issued and outstanding shares of common stock.
Significantly increased share count and affected per-share metrics; part of two reverse splits within approximately nine months. - Cash concentration risk
The company had $15,097,241 and $7,580,820 in excess of FDIC insured limits of $250,000 at September 30, 2026 and December 31, 2025, respectively.
Concentration risk has increased as cash balances have grown from financing activities.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow GNPX in real time
Get material earnings, filing, IR, and earnings-call alerts by email.